 PARIS CAMBRIDGE, Mass.--BUSINESS WIRE--- NBTX ASCO--Regulatory News: NANOBIOTIX Euronext : NANO NASDAQ: NBTX the Company, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the upcoming presentation of updated data from the Companys immunotherapy development pathway at the 2021 Annual Meeting of the American Society for Clinical Oncology ASCO. Cancer immunotherapies such as anti-PD-1 hav 